Biogen Downgraded On Pipeline Setbacks And Leqembi Sales Slowdown
Jefferies downgraded Biogen Inc (NASDAQ:BIIB), citing the company’s tough setup. Leqembi (lecanemab) sales growth remains ...
Pablo Villoslada, Spanish neurologist: “What is going to happen is a revolution in the treatment of Alzheimer's and other dementias”
A few days ago, the European Medicines Agency approved a new drug to delay or slow down the progression of Alzheimer's ...
Biogen expects steady growth for Alzheimer's drug Leqembi in near term
Biogen expects growth of its keenly watched Alzheimer's disease drug, Leqembi, to see a "linear trend" in the United States ...
Grasping for hope: The heartbreaking journey through Alzheimer’s drug trials
For spouses who care for a partner with Alzheimer’s disease, every day brings a different battle and a new challenge. Every ...
Does Medicare cover Leqembi?
Medicare Part B covers Leqembi for people with early Alzheimer's or mild cognitive impairment. Learn more about Leqembi and Medicare coverage here.
The Register-Herald23h
Rockefeller Neuroscience Institute expands access to groundbreaking Alzheimer’s treatment
The WVU Rockefeller Neuroscience Institute (RNI) is providing patients greater statewide and regional access to a ...
A health system that is sick: America must treat its chronic disease crisis
The nomination of Robert F. Kennedy Jr. as secretary of health and human services has sparked considerable outrage, focused ...
Eisai And Biogen : Mexico Approves LEQEMBI For Early Alzheimer's Disease Treatment
Eisai Co., Ltd. (ESALF.PK) and Biogen Inc. (BIIB) announced that the Federal Commission for the Protection Against Sanitary Risk ...
The Victoria Advocate10d
"LEQEMBI®" (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in Mexico
TOKYO and CAMBRIDGE, Mass., Dec. 4, 2024 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate ...
Yahoo Finance9d
Leqembi® approved in Mexico
STOCKHOLM, Dec. 4, 2024 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) ...
Reuters11d
Biogen expects steady growth for Alzheimer's drug Leqembi in near term
Dec 3 (Reuters) - Biogen (BIIB.O), opens new tab expects growth of its keenly watched Alzheimer's disease drug, Leqembi, to see a "linear trend" in the United States in the near term, a company ...